Sanofi Consumer Healthcare India Limited announced financial results for the second quarter of 2025.

The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore, supported by export operations and product launches. Sales growth stood at 27.5% from Q1 2025 and 27.6% YoY from 2024. Profit after tax (PAT) for the quarter reached Rs. 60.7 crore, a 21% increase over Q1 2025.

Commenting on the results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, said “Our commitment to delivering high-quality, science-backed products continues to guide our growth strategy—driven by a focused portfolio, research-led innovation, and an agile organization. This quarter reflects the outcomes of that approach, with the relaunch of two previously recalled products and the introduction of a new product. We also began export operations, expanding into international markets. As we look ahead, we remain focused on making self-care simpler, more accessible, and effective for consumers.”

During the half year, the company launched Allegra D in the allergy segment and relaunched Depura 60k and Combiflam Suspension, which were voluntarily recalled last year. Legacy brands such as Avil and Depura continue to maintain consumer trust and relevance in their categories.